Novartis, Incyte: CHMP Backs Jakavi in Graft-Vs-Host Disease
March 25 2022 - 9:22AM
Dow Jones News
By Colin Kellaher
Novartis AG and Incyte Corp. on Friday said the European
Medicines Agency's Committee for Medicinal Products for Human Use
recommended expanded approval of the blood-cancer drug Jakavi for
the treatment of acute and chronic graft-versus-host disease.
The companies said the recommendation covers the treatment of
patients ages 12 and up who have inadequate response to
corticosteroids or other systemic therapies.
The European Commission, which generally follows the CHMP's
advice, would now review the recommendation, with a decision
expected within about two months.
The companies said Jakavi, if approved, would be the first
JAK1/2 inhibitor available in Europe for patients with
graft-versus-host disease, a condition in which donated bone marrow
or stem cells attack a transplant recipient's organs.
Under a long-running collaboration, Wilmington, Del.,
biopharmaceutical company Incyte markets the drug as Jakafi in the
U.S., while Switzerland's Novartis markets it as Jakavi outside the
U.S.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 25, 2022 09:07 ET (13:07 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024